Jupiter Neurosciences, Inc. JUNS 深 沪
已收盘 02-06 16:00:00 美东时间
0.5994
-0.016
-2.65%
华盛通- 最 高0.6079
- 今 开0.5972
- 成交量 9.75万股
- 最 低 0.5732
- 昨 收 0.6157
- 总市值 2063.52万
- 52周最高 3.33
- 市盈率 静 --
- 换手率 0.28%
- 52周最低 0.48
- 委 比 28.95%
- 总股本 3442.64万
- 历史最高 19.51
- 量 比 0.46
- 振 幅 5.64%
- 历史最低 0.48
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users
BRIEF-Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users Jan 28 (Reuters) - Jupiter Neurosciences Inc JUNS.O : JUPITER NEUROSCIENCES INC - ANNOUNCES STRATEGIC INITIATIVE FOR GLP-1 USERS Source text: ID:nGNX8RPntl Further company coverage: JUNS.O (( Reuters.Briefs@thom
01-28 19:02
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Jupiter Neurosciences announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ product line. The initiative aims to address biological pressures on mitochondrial energy production, lean tissue preservation, and neuro-gut inflammatory balance. By leveraging mitochondrial health and cellular resilience, Nugevia™ provides a complementary solution to enhance long-term metabolic resilience an...
01-28 11:00
Jupiter Neurosciences to Present at DealFlow Discovery Conference in Atlantic City
Jupiter Neurosciences to Present at DealFlow Discovery Conference in Atlantic City Jupiter Neurosciences, Inc. will participate in the 3rd Annual DealFlow Discovery Conference, taking place January 28-29, 2026, at The Borgata Hotel, Casino & Spa in Atlantic City, NJ. Chairman and CEO Christer Rosén
01-27 23:45
Jupiter Neurosciences Expands Equity Financing Through SEPA Advances
Jupiter Neurosciences, Inc. ( ($JUNS) ) has issued an announcement. On October ...
2025-12-24 06:49
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter Neurosciences invites investors to a webinar on January 6, 2026, to discuss its JOTROL™ platform and upcoming Phase 2a trial for Parkinson’s disease. The presentation by CEO Chister Rosén will cover the company’s dual-path strategy, including its Nugevia™ longevity products and clinical development plans. Registration and Q&A details are provided, along with information on the company’s innovative resveratrol-based technology and therapeu...
2025-12-23 13:00
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
Jupiter Neurosciences, Inc. has received FDA clearance to initiate a Phase 2a clinical trial of its JOTROL™ therapy for Parkinson’s disease. The trial aims to evaluate safety, tolerability, and pharmacokinetics of JOTROL, which has shown strong bioavailability and potential neuroprotective benefits. JOTROL’s enhanced delivery system offers over nine times higher bioavailability than traditional resveratrol. The Company expects to begin enrollment...
2025-11-05 13:30
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Jupiter Neurosciences, Inc. (JUNS) has secured up to $20 million in financing from Yorkville Advisors to support its Phase 2 Parkinson's disease trial and expand its Nugevia™ product line. The funding includes a $6 million pre-paid advance and up to $14 million under a Standby Equity Purchase Agreement (SEPA). JUNS plans to use the proceeds for the Phase 2 trial of JOTROL™, its resveratrol delivery platform, and to accelerate marketing and sales ...
2025-10-27 12:30
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
Jupiter Neurosciences announced the addition of Jean Fallacara, a biohacking pioneer and entrepreneur, as the third品牌大使 for Nugevia™, its new consumer longevity supplement line. Nugevia™ leverages the JOTROL™ platform, a patented resveratrol-based delivery system, to enhance bioavailability and support cellular health. With a focus on longevity and resilience, the product line aims to tap into the fast-growing longevity market, projected to reach...
2025-09-15 12:00
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
<p>Jupiter Neurosciences, Inc. announced the launch of its Nugevia™ e-commerce platform and pre-orders for three nutraceutical supplements targeting longevity and wellness. The products, enhanced with the company’s JOTROL™ resveratrol delivery platform, offer improved bioavailability and are designed to support skin health, energy, and cognitive function. The launch supports Jupiter’s dual-path strategy, combining CNS therapeutic development with...
2025-08-26 12:00
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
Jupiter Neurosciences, Inc. announced that NBA Hall of Fame Chris Webber has joined as the brand ambassador for its new longevity supplement line, Nugevia™. Webber, known for his championship mindset and dedication to peak performance, aligns with Nugevia’s mission to support longevity, resilience, and elite performance backed by clinical science. Nugevia™, powered by Jupiter’s patented JOTROL™ technology, offers enhanced bioavailability and is d...
2025-08-19 12:12
